$HUMA News

Humacyte at ASN Kidney Week: Phase 3 Trial Built for Women Shows ATEV Advantage Over Fistula, Getting Patients Off Catheters Months Sooner

Humacyte Presents Interim Results From V012 Phase 3 Clinical Trial Of Acellular Tissue Engineered Vessel In Arteriovenous Access For Female Hemodialysis Patients, At ASN Kidney Week 2026

Why Humacyte, Inc. (HUMA) Outpaced the Stock Market Today

Humacyte, Inc. (HUMA) Stock Drops Despite Market Gains: Important Facts to Note

Humacyte Provides Commercial Update and Highlights Rapid Acceleration of Symvess Adoption by Hospitals

Humacyte Reports Accelerating Commercial Adoption, Reports 44% Increase In Hospitals Ordering Symvess To 49 In Q3 2026

Humacyte, Inc. (HUMA) Sees a More Significant Dip Than Broader Market: Some Facts to Know

Humacyte Announces Phase 3 V012 Trial Results for ATEV in Women Requiring Hemodialysis Access Accepted for a Late-Breaking Session Presentation at ASN Kidney Week 2026

Humacyte (HUMA) Stock Fair Value Moves Lower After Analyst Target Cuts

Barclays Initiates Coverage On Humacyte with Equal-Weight Rating, Announces Price Target of $0.5

Humacyte, Inc. (HUMA) Stock Slides as Market Rises: Facts to Know Before You Trade

Humacyte, Inc. (HUMA) Stock Drops Despite Market Gains: Important Facts to Note

Humacyte Expands Board Expertise with Appointment of Scott Coward and Paul Kuznik

Humacyte, Inc. (HUMA) Stock Sinks As Market Gains: Here's Why

Humacyte, Inc. (HUMA) Beats Stock Market Upswing: What Investors Need to Know

Is Humacyte, Inc. (HUMA) a Buy as Wall Street Analysts Look Optimistic?

Humacyte to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Humacyte Announces FDA Authorization Extending Symvess Shelf Life to 36 Months

Humacyte Receives FDA Authorization To Extend The Expiration Dating Period For Symvess From 18 To 36 Months

Humacyte Confirms Plans for ATEV Supplemental BLA Filing for Dialysis Access Following FDA Discussions